Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with newly or formerly diagnosed moderate to severe COPD (Patients with postbronchodilator FEV1/FVC ratio \<0.70, and FEV1 \<80% of predicted normal. Patients have chronic cough or chronic productive cough with breathlessness even walking slowly along flat ground.) Current smokers or exsmokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Females patients with childbearing potential using effective birth control method~* Patients who has a capability of communicate with investigator~* Patients who accept to comply with the requirements of the protocol~* Patients who signed written informed consent prior to participation~Exclusion Criteria:~* Patients who have history of hypersensitivity to drugs contains long-acting beta2-agonist or corticosteroids~* Patients who have abnormal blood glucose level ((≥140 mg/dl)~* Patients who have unregulated diabetes mellitus~* Patients who have a serum potassium level of ≤3.5 mEq/L or \>5.5mEq/L~* Patients who have asthma~* Patients who have a history of myocardial infarction, severe hearth failure, acute ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks~* Patients who have lung cancer~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period.~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period.~* Women who are pregnant or nursing~* History of allergic rhinitis or atopy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Formoterol/Budesonide 12/400 mcg Discair (Type: EXPERIMENTAL): Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®

Based on this trial design, predict the completion outcome and termination type (if applicable).